Caring to make a difference

December 2009

December 12th, 2009 · No Comments

Genscreen announces the interim results of its preclinical development projects.
RESET monoclonal antibody has been produced and is ready for animal testing in cancer model.
RESET ELISA has now been developed and validated and is ready for use.
TR400 has been tested in 2-D and 3-D melanoma models and has also been tested in animal model of cancer.

Tags: news

0 responses so far ↓

  • There are no comments yet...Kick things off by filling out the form below.

Leave a Comment